Short Interest in Immatics (NASDAQ:IMTXW) Drops By 12.5%

Immatics (NASDAQ:IMTXW) was the recipient of a large decrease in short interest during the month of March. As of March 31st, there was short interest totalling 1,400 shares, a decrease of 12.5% from the March 15th total of 1,600 shares. Based on an average daily volume of 4,000 shares, the days-to-cover ratio is currently 0.4 days.

Immatics Stock Performance

Shares of NASDAQ IMTXW opened at $2.70 on Tuesday. Immatics has a 1-year low of $1.39 and a 1-year high of $4.14. The business has a fifty day moving average price of $3.28 and a 200 day moving average price of $2.96.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in IMTXW. Aristeia Capital LLC increased its position in Immatics by 3,293.6% during the 4th quarter. Aristeia Capital LLC now owns 754,590 shares of the company’s stock valued at $1,856,000 after buying an additional 732,354 shares in the last quarter. Alyeska Investment Group L.P. acquired a new position in Immatics during the 4th quarter valued at about $529,000. Walleye Capital LLC increased its position in Immatics by 25.7% during the 2nd quarter. Walleye Capital LLC now owns 260,079 shares of the company’s stock valued at $889,000 after buying an additional 53,153 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Immatics by 11.9% in the second quarter. JPMorgan Chase & Co. now owns 378,197 shares of the company’s stock valued at $1,293,000 after purchasing an additional 40,168 shares during the period. Finally, Jefferies Financial Group Inc. acquired a new position in shares of Immatics in the fourth quarter valued at about $80,000.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.